Abstract:617 Background: Pancreatic cysts are rarely symptomatic, and, consequently, are detected incidentally during routine imaging analyses for unrelated disorders. Guidelines for diagnosis of pancreatic cysts rely on imaging and supportive analyses of fluid extracted during endoscopic ultrasound with fine-needle aspiration (EUS-FNA). Unfortunately, currently available protein markers and assays are not sufficiently accurate to rule-out patients in whom a non-mucinous pancreatic cyst has formed. Since non-mucinous pancreatic cysts seldom progress to cancer, this patient population is at risk of being subjected to the severe physical, emotional, and financial burdens associated with unwarranted surveillance, testing, and possible surgical intervention. Furthermore, identification of mucinous pancreatic cysts does not establish the risk of progression to cancer (rule-in) or the need for surgical intervention. Methods: To address the unmet needs in pancreatic cyst diagnosis, Amplified Sciences has combined a panel of markers with a clinically translated surface enhanced Raman spectroscopy (SERS)-based protease activity assay as a rule-out diagnostic tool. The tri-analyte panel was tested on a cohort of 185 retrospective samples gathered from three separate institutions (UPMC, IU Health, and UCSF) and consumed only 12 μL of cyst fluid per sample. The goals of this study were to establish the negative predictive value (NPV) of this panel prior to translation to a CLIA-regulated laboratory and create a preliminary algorithm for analysis. Results: The results of this statistically powered study show that protease activity outperforms carcinoembryonic antigen (CEA), a current standard diagnostic marker for pancreatic cyst fluid, in sensitivity, specificity, and NPV. Furthermore, in combination, the tri-analyte panel identifies non-mucinous pancreatic cysts with 99% sensitivity and a negative predictive value >95%. Conclusions: These results support the use of this panel in clinical settings as a diagnostic tool to rule-out patients from surgical intervention, as well as the use of SERS as an optical detection mode for clinical diagnostics. Future work will continue to address the unmet need for improved diagnostic information through multiplexed analyses of markers that consume comparatively minimal volume of pancreatic cyst fluid samples. Studies will also seek to build on the SERS platform by introducing more dyes, substrates, assays, and analytical methods. Amplified Sciences would like to acknowledge significant efforts to build the clinical samples cohort from Gina Zhu, Kelli Ifuku, and Dr. Kimberly Kirkwood from USCF, Christine Decapite and Dr. Randall Brand from UPMC, and Michele Yip-Schneider and Dr. C. Max Schmidt from IU Health.

Analysis of Clinical Samples of Pancreatic Cyst's Lesions with A Multi‐Analyte Bioelectronic Simot Array Benchmarked Against Ultrasensitive Chemiluminescent Immunoassay (Adv. Sci. 27/2024)

Analysis of Clinical Samples of Pancreatic Cyst's Lesions with A Multi‐Analyte Bioelectronic Simot Array Benchmarked Against Ultrasensitive Chemiluminescent Immunoassay

A large-area organic transistor with 3D-printed sensing gate for noninvasive single-molecule detection of pancreatic mucinous cyst markers

Diagnosis of pancreatic adenocarcinoma using protein chip technology.

Evaluation of the Effectiveness of a Chemoprevention Model of Pancreatic Adenocarcinoma Using Protein Chip Technology.

Homogeneous Multiplex Immunoassay for One-Step Pancreatic Cancer Biomarker Evaluation

Development of a multi-analyte blood test for the early detection of pancreatic ductal adenocarcinoma (PDAC) and performance compared to CA19-9.

Amplified Sciences PanCyst Pro Panel to accurately identify non-mucinous pancreatic cyst fluid.

The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer

Accelerated Exosomal Metabolic Profiling Enabled by Robust On‐Target Array Sintering with Metal–Organic Frameworks

Stratifying Risk for Pancreatic Cancer by Multiplexed Blood Test

Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins

Single Molecule with a Large Transistor – SiMoT cytokine IL‐6 Detection Benchmarked against a Chemiluminescent Ultrasensitive Immunoassay Array

4532 Pancreatic Cyst Risk Stratification for Early Detection of Pancreatic Cancer Using Quantitative Radiomics and Activity-Based Biomarkers

Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification

Translation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts

Multiplex measurement of twelve tumor markers using a GMR multi-biomarker immunoassay biosensor

Multiplex detection of pancreatic cancer biomarkers using a SERS-based immunoassay

Highly sensitive microfluidic sensor using integrated optical fiber and real-time single-cell Raman spectroscopy for diagnosis of pancreatic cancer

Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma

Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer